Background: Unrelated individuals (n = 242) were interviewed directly for the presence of migraine, anxiety disorders, and major depression. Materials and Methods: The data described in this study are derived from a clinical genetic relational database that was developed initially for the genetic analysis of migraine. Genotyping of the DRD2 NcoI C to T polymorphism located in exon 6 (His3 1 3His) was performed using previously described primers. Results: A significantly increased incidence of migraine with aura (MWA), major depression, generalized anxiety disorder (GAD), panic attacks, and phobia was observed in individuals with the DRD2 NcoI C/C genotype compared with individuals with an DRD2 NcoI T allele. Specifically, 69% (91/131) of DRD2 NcoI C/C individuals
Introduction
Striking similarities exist between the epidemiological characteristics of migraine, anxiety, and depression (1) (2) (3) (4) (5) . All three disorders afflict approximately 10% to 25% of the general population at some point in life and are approximately twice as common in females as in males. Prophylactic medications for all three disorders have a subacute onset of action, requiring 3 to 6 weeks of therapy to measure clinical improvement. In epidemiological studies, a clinical diagnosis of migraine significantly increases the risk of comorbid anxiety and depression (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Taken together, these data suggest that a common metabolic variation may underlie comorbid migraine, anxiety and depression.
In a recent molecular genetic study, an association was observed between the NcoI polymor-phism in exon 6 of the dopamine D2 receptor (DRD2) and the clinical susceptibility to migraine with aura (MWA) (16) . We therefore performed an association analysis of DRD2 NcoI alleles in a group of 242 unrelated individuals, approximately half of whom suffer from MWA, anxiety disorders, and/or major depression. The present study was designed to analyze the possible association of DRD2 NcoI alleles with comorbid neuropsychiatric disorders.
Materials and Methods
The data described in this study are derived from a clinical genetic relational database that was developed initially for the genetic analysis of migraine (17) . Potential subjects were identified by physician or self-referral for a migraine genetic study. Subjects were evaluated using a semistructured interview for migraine. Migraine evaluations were conducted by a neurologist and/or trained interviewer. The lifetime presence or absence was determined for each of the criteria in the International Headache Society (IHS) definition of MWA (18) .
A semi-structured interview based on the Structured Clinical Interview for DSM-HI-R (SCID) (19) , modified to include the criteria of the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) (20, 21) was used to evaluate anxiety and depressive disorders in the same individuals interviewed for migraine. The interview included questions that were appropriate to establish a DSM-IV-based diagnosis of generalized anxiety disorder (GAD), phobias, panic attacks, panic disorder, obsessive-compulsive disorder (OCD), and major depression. Interviews were performed by physicians or trained psychiatric nurses. Diagnoses required the concurrence of at least three physicians.
Genomic DNA was isolated using the Puregene DNA isolation kit (Gentra Systems, Research Triangle Park, NC). Genotyping of the DRD2 NcoI C to T polymorphism located in exon 6 (His313His) was performed using previously described primers (22) . Briefly, 40 Table 1 , anxiety disorders are the most common diagnosis, being present in 46% (122/242) of the current dataset. Major depression is the single most common diagnosis (i.e., 38%) amongst the group of analyzed disorders in the present study. The incidences of panic attacks (31%) and phobia (29%) are similar. MWA is present in 21% of the individuals. Panic disorder, GAD, and OCD are present in less than 20% of the current study group.
A distribution of the comorbidities is provided in Table 2 . These data are consistent with previous reports on neuropsychiatric comorbidities. For example, approximately 50% of individuals with MWA report a history of major depression (13, 13, 23) . Individuals with panic attacks have the highest incidence of comorbid MWA (78%) in the present study. Obsessive compulsive disorder 14 86 0
Results from current study (n = 242). Clinical diagnoses were based on DSM criteria for anxiety disorders (20) and major depression (21) and on IHS criteria for MWA (18) . If a clear diagnosis could not be made, the individual was not diagnosed and was not included in further statistical analyses for the disorder.
Frequency of Neuropsychiatric Disorders Based on DRD2 NcoI Genotypes
The incidences of the various clinical diagnoses based on DRD2 NcoI genotypes is provided in Table 3 . A present or past history of MWA, anxiety disorders, or major depression is present in 69% of the C/C individuals, 53% of the C/T individuals, and 22% of the T/T individuals. The incidence of any of these neuropsychiatric diagnoses is significantly higher in the C/C individuals when compared to either the C/T individuals (Chi-square = 6.53; p < 0.005), T/T individuals (Chi-square = 15.29; p < 0.00005), or the combined T/any group of individuals (Chi-square = 12.72; p < 0.0002).
The presence of an anxiety disorder is significantly more frequent in the C/C individuals than in either the C/T individuals (Chi-square = 3.87; p < 0.02), T/T individuals (Chi-square = 8.92; p < 0.001), or the combined T/any group of individuals (Chi-square = 7.20; p < 0.004). A similar pattern is seen with GAD. Major depression, panic attacks, MWA, and phobia are also all increased significantly in the C/C versus T/any individuals (Table 3) . Although both panic disorder and OCD are more frequent in the C/C ver- Results from current study (n = 242). Clinical diagnoses were based on DSM criteria for anxiety disorders (20) and major depression (21) and on IHS criteria for MWA (18) . The major finding of the present study is that the individuals based on the presence or absence of incidence of the clinical diagnoses of MWA, anxthe neuropsychiatric disorders analyzed in the iety disorders, and major depression are comorpresent study (Table 4 ). In individuals with bidly associated with the NcoI polymorphism MWA, anxiety disorders, and/or major depreswithin the DRD2 gene. This is the first known sion, the C allele frequency is 0.80 and the T association study of the DRD2 NcoI polymorallele frequency is 0.20. In individuals who have phism in neuropsychiatric disorders. As demonnone of these neuropsychiatric disorders, the C strated in the present study, individuals with allele frequency is 0.63, and the T allele fremigraine, anxiety, and/or depression display an quency is 0.37. The difference in the DRD2 NcoI increased frequency of the DRD2 NcoI C/C geno-C allele frequencies between these two groups of type compared to individuals with the C/T or T/T individuals is highly significant (Chi-square = genotype. These data represent the first direct 17.13; p < 0.00002). These data are consistent evidence to suggest that a specific genetic variant with the allele frequencies reported in the genmay, at least partially, underlie the well-docu- Results from current study. Clinical diagnoses were based on DSM criteria for anxiety disorders (20) and major depression (21) and on IHS criteria for MWA (18) .
mented comorbidity of migraine, anxiety disorders, and major depression (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
Multiple previous association studies of other DRD2 polymorphisms have focused on other neuropsychiatric disorders. For example, the DRD2 TaqI Al allele was reported to be a risk factor in the polygenic inheritance of Tourette's syndrome, stuttering, attention deficit hyperactivity, conduct and oppositional defiant disorder (24) . In the early 1990s, numerous groups reported an association between the DRD2 TaqI Al allele and alcoholism (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , although the putative association was not confirmed by other investigators (35) (36) (37) (38) (39) . Numerous reviews of all available data have tended to conclude that an association probably does exist between the DRD2 variants and certain forms of alcoholism (40) (41) (42) (43) .
Significant associations have also been reported between DRD2 polymorphisms and polysubstance substance abuse (43) (44) (45) (46) (47) . A single report suggested an association between the S3 1 1 C variant of the DRD2 receptor and schizophrenia (48) , although this finding was not confirmed by other investigators (49) (50) (51) . Individuals with the DRD2 HphI B2 allele were reported to display a decrease in mature, and an increase in neurotic and immature, defense styles compared to individuals without this DRD2 allele (52) . Thus, a variety of DRD2 polymorphisms have been associated with numerous neuropsychiatric disorders. A key unanswered question concerns the possible mechanism by which these polymorphisms might affect gene function.
In postmortem brain samples, Taq A DRD2 alleles are associated with variations in the density of DRD2 binding sites (26) . No data exist at present on the effect of NcoI polymorphisms on DRD2 expression. Conceivably, intragenic nucleotide variations may result in functional variations in RNA stability or efficacy in transcription (53) , thus resulting in alterations in the density of the expressed receptor protein. For example, recent data suggest that noncoding region variations within the 5-hydroxytryptamine transporter (5-HTT) gene may alter expression of the transporter (54) . Specifically, the transcriptional efficiency of the short variant of the 5-HTT gene is reduced compared to the long version of the gene (55 (57) . Future studies are needed to more clearly define the possible functional significance of noncoding region variations within the DRD2 gene.
The association data reported in the present study confirm and extend multiple previous epidemiological studies on migraine and psychiatric comorbidities (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In a study of 133 index cases with major depression versus control index cases and their first-degree relatives (6), a strong association was observed between migraine and depression. Specifically, in the first-degree relatives of control subjects, the incidence of migraine (7%) and depression (10%) was significantly lower than the incidence of migraine (22%) and depression (19%) in the first-degree relatives of depressed subjects. If an index case had both migraine and depression, the individual had a 75 % chance of having a comorbid anxiety disorder (6) . No association with migraine was found for alcoholism, substance abuse, antisocial personality, obsessive-compulsive disorder or schizophrenia. The authors concluded that "depression may be either a sequela of migraine or the diathesis which results in both migraine and depression." However, they "could not definitely resolve whether the source of correlation between the two disorders was attributable to a transmissible or a non-transmissible common component or both."
An association between migraine and depression was also demonstrated in a study of an unselected epidemiological sample with a standardized assessment of psychiatric diagnoses (7) . Migraine patients were noted to have a significantly increased incidence of major depression, bipolar spectrum, general anxiety, panic disorder and phobias. The migraine subjects reported a significantly earlier onset of anxiety symptoms than nonmigraine subjects as evidenced by a high incidence of being more anxious than their peers during childhood. The authors suggested that "migraine with anxiety and depression may constitute a distinct syndrome comprising anxiety, often manifested in early childhood, followed by the occurrence of migraine headaches, and then by discrete episodes of depressive disorder in adulthood" (7) .
A prospective study has also documented an association between migraine and depression/ anxiety (23) wherein a history of migraine was found to carry a 4-fold increased incidence of depression. These authors also found a temporal pattern with anxiety preceding migraine, followed by depression (8) and concluded that migraine, anxiety disorders and major depression might share common predispositions, "although the nature of these predispositions remains to be determined" (23) . By contrast, the present study provides strong evidence for a shared genetic predisposition to comorbid migraine, anxiety and depression.
In conclusion, the present data indicate that MWA, anxiety disorders and major depression are comorbidly associated with the NcoI polymorphism within the DRD2 gene. As a result, these disorders should not necessarily be considered as independent disorders. Rather, the data indicate that a distinct clinical syndrome may be expressed as a manifestation of a single underlying genetic variation. The clinical recognition that all three disorders may be associated with the same genetic variant has significant diagnostic and therapeutic implications since DRD2 antagonists have been shown to be effective therapeutic agents for a subset of individuals with these common disorders.
